Ustekinumab is NOT recommended for people with psoriatic arthritis in the UK

The use of ustekinumab (Stelara) as a new therapy for psoriatic arthritis has been given the red light by the UK’s National Institute for Health and Care Excellence (NICE).
The efficacy of the drug compared to other therapies has been called into question along with its cost effectiveness.
But people currently receiving ustekinumab for psoriatic arthritis can continue treatment until they and their clinicians consider it appropriate to stop.
“Whilst recognising the severity of the disease, the committee concluded that ustekinumab could not be considered a good use of NHS resources,” says Sir Andrew Dillon, chief executive of NICE. ”NICE currently recommends golimumab, adalimumab, etanercept and infliximab for treating active and progressive psoriatic arthritis in adults.”